Skip to main content

Table 2 Determination for risk factors for DFS or OS by univariate tests

From: The use of non-steroid anti-inflammatory drugs during radical resection correlated with the outcome in non-small cell lung cancer

 

DFS

OS

 

P

HR (95% CI)

P

HR (95% CI)

Age (y)

 < 60

1

 

1

 

 ≥ 60

0.033*

1.78 (1.05–3.01)

0.072

2.09 (0.94–4.64)

Sex

 Male

1

 

1

 

 Female

0.001*

0.37 (0.21–0.66)

0.002*

0.19 (0.06–0.55)

Type of resection

 Lobectomy

1

 

1

 

 Segmentectomy

0.105

1.86 (0.88–3.95)

0.100

3.37 (0.79–14.32)

Pathology

 ADC

1

 

1

 

 SCC

0.196

1.84 (0.73–4.67)

0.023*

3.52 (1.19–10.44)

 Others

0.006*

4.28 (1.53–12.02)

0.091

3.54 (0.82–15.34)

Smoking status

 Never

1

 

1

 

 Current + former

 < 0.001*

3.19 (1.88–5.40)

 < 0.001*

4.45 (1.96–10.08)

Alcohol status

 Never

1

 

1

 

 Current + former

0.126

1.51 (0.89–2.57)

0.024*

2.49 (1.13–5.49)

Comorbidity

 With

1

 

1

 

 Without

0.880

0.95 (0.52–1.75)

0.295

0.57 (0.19–1.65)

T stages

 T1 + T2

1

 

1

 

 T3 + T4

0.002*

5.16 (1.86–14.31)

0.058

4.07 (0.95–17.37)

N stages

 N0

1

 

1

 

 N1 + N2

 < 0.001*

9.70 (5.63–16.71)

 < 0.001*

14.47 (6.26–33.46)

TNM stages

 I

1

 

1

 

 II

 < 0.001*

7.06 (3.66–13.64)

 < 0.001*

9.34 (3.50–24.92)

 III

 < 0.001*

20.36 (12.74–50.49)

 < 0.001*

24.23 (9.23–63.60)

NSAIDs UI

 Low

1

 

1

 

 High

0.001*

0.38 (0.21–0.68)

0.010*

0.27 (0.10–0.73)

  1. UI use intensity, ADC adenocarcinoma, SCC squamous carcinoma, DFS disease-free survival, OS overall survival
  2. *With significant difference